Nonalcoholic fatty liver disease: Biomarkers support decisions around pharmacological intervention.

SILVIA SOOKOIAN; CARLOS J. PIROLA

HEPATOLOGY (BALTIMORE, MD.)

JOHN WILEY & SONS INC

Lugar: New York; Año: 2017 vol. 65 p. 1417 - 1419

0270-9139

We have previously observed in a case-control study(215 individuals) that patients with NAFLD haveincreased levels of biomarkers of atherosclerosis,including PAI1, soluble intercellular adhesion molecule1, and sCD40. To extend these observations, wemeasured, by immunohistochemistry, their hepaticprotein expression.(2) We found that liver PAI1immunoreactivity was significantly associated withdisease severity; PAI1 was expressed in hepatocytes aswell as in the inflammatory infiltrate.(2) To furtherevaluate the effect of losartan, an angiotensin II type 1receptor (AT1R) antagonist, and telmisartan, anAT1R-blocker with insulin-sensitizing properties, onhepatic expression of PAI1 (Serpine1), we used a ratmodel of NAFLD.